The use of AI technologies in healthcare has evolved at a breathtaking rate in the last few years. Hype and hypotheticals have been replaced with real, practical tools that help physicians focus on providing high-quality care. 

3D surface modeling and virtual surgical planning are expanding radiology’s contribution to multidisciplinary teams. Together, AI-driven interpretation and 3D-enabled clinical collaboration represent two distinct, complementary forces shaping the next decade of radiology.

As radiology departments across the US continue to navigate the complexities of the current imaging market, including disruptions in supply chains and increased demand for CT contrast media, one constant remains: the need for reliable, quality supply partners to help sustain patient care. 

DocMoonlight, the nation’s largest provider of onsite contrast supervision, and ContrastConnect, the largest provider of virtual contrast supervision, today announced a strategic collaboration designed to offer imaging organizations the most complete, flexible, and scalable contrast supervision solution in the industry. By aligning their complementary strengths, the partnership is aimed at expanding patient access, enhancing patient safety, and meeting growing imaging demands across diverse regulatory environments.

Let’s conduct a quick thought experiment. We enter a time machine and set the controls for Connecticut in 2015. As luck would have it, we land in a meeting room of the imaging department at the Yale-New Haven Health system. There we overhear a conversation. Imaging aficionados that we are, we quickly realize two groups are present—IT leaders and ranking radiologists. It’s hard to make out the exact words through the time warp. However, we clearly hear one term repeated several times: “deconstructed PACS.” 

TAVR is increasingly seen as the preferred option for symptomatic severe aortic stenosis, and clinical guidelines in the U.S. reserve their highest recommendations for patients who experience symptoms. Asymptomatic patients, meanwhile, are typically managed by clinical surveillance or a “watch and wait” approach; no symptoms means no treatment.

As the leading provider of generic contrast agents, Fresenius Kabi’s commitment is to provide you with choice and value – by continuing to grow their radiology portfolio. We look forward to seeing you at RSNA 2025 | Booth #3247 | South Hall 

Six years ago, two radiologists with dissimilar backgrounds and divergent clinical interests put their heads together and launched a new practice. One physician was an academic subspecialized in musculoskeletal reads. The other, a private practitioner, concentrated on oncologic imaging. That’s how Transparent Imaging was born, powered by Konica Minolta.